Pan-cancer transcriptome analysis reveals a gene expression signature for the identification of tumor tissue origin

Modern Pathology

Volumn 29, Issue 6, 2016, Pages 546-556

  Xu, Qinghua ^a   Chen, Jinying ^a   Ni, Shujuan ^b,c   Tan, Cong ^b,c   Xu, Midie ^b,c   Dong, Lei ^b,c   Yuan, Lin ^d   Wang, Qifeng ^b,c   Du, Xiang ^b,c  

^a Canhelp Genomics ^*  (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN D; ASPORIN; CALRETININ; CARBONATE DEHYDRATASE XII; CARBOXYPEPTIDASE B1; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CHITINASE 3 LIKE 1 PROTEIN; CHROMOGRANIN A; CHROMOGRANIN B; CLAUDIN 11; CLAUDIN 18; CLUSTERIN; COLLAGEN TYPE 11 ALPHA 1; CREATINE KINASE BB; CXCL14 CHEMOKINE; DOPACHROME TAUTOMERASE; DOPAMINE BETA MONOOXYGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; ESTROGEN RECEPTOR ALPHA; FATTY ACID BINDING PROTEIN 1; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON; GLUTATHIONE PEROXIDASE 3; HLA DQA1 ANTIGEN; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; UNCLASSIFIED DRUG; TUMOR MARKER;

ADRENAL CORTEX CARCINOMA; ARTICLE; BRAIN TUMOR; BREAST CARCINOMA; CANCER OF UNKNOWN PRIMARY SITE; COLORECTAL CARCINOMA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MALE; MELANOMA; MESOTHELIOMA; METASTASIS; MICROARRAY ANALYSIS; NEUROENDOCRINE TUMOR; NEXT GENERATION SEQUENCING; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; TESTIS CARCINOMA; THYROID CARCINOMA; TUMOR DIFFERENTIATION; URINARY TRACT CARCINOMA; UTERINE CERVIX CARCINOMA; BIOLOGY; CLASSIFICATION; DNA MICROARRAY; GENETIC DATABASE; GENETICS; HIGH THROUGHPUT SEQUENCING; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; VALIDATION STUDY;

BIOMARKERS, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; NEOPLASMS, UNKNOWN PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME;

EID: 84961223626     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.60     Document Type: Article

References (50)

1. Stella GM, Senetta R, Cassenti A, et al. Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med. 2012; 10: 12.
2. Richardson A, Wagland R, Foster R, et al. Uncertainty and anxiety in the cancer of unknown primary patient journey: a multiperspective qualitative study. BMJ Support Palliat Care. 2015; 5: 366-372.
3. Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005; 54: 243-250.
4. Kamposioras K, Pentheroudakis G, Pavlidis N. Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks. Eur J Clin Invest. 2013; 43: 491-500.
5. Kurahashi I, Fujita Y, Arao T, et al. A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer. PLoS One. 2013; 8: e63249.
6. Hyphantis T, Papadimitriou I, Petrakis D, et al. Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology. 2013; 22: 2009-2015.
7. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, 'Onko-PET III', 21 July and 19 September 2000. Eur J Nucl Med. 2001; 28: 1707-1723.
8. Horlings HM, van Laar RK, Kerst JM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008; 26: 4435-4441.
9. Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008; 26: 4442-4448.
10. Talantov D, Baden J, Jatkoe T, et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006; 8: 320-329.
11. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-Time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006; 130: 465-473.
12. Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005; 65: 4031-4040.
13. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008; 26: 462-469.
14. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-Analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 2004; 101: 9309-9314.
15. Piccolo SR, Sun Y, Campbell JD, et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics. 2012; 100: 337-344.
16. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005; 33: e175.
17. Omberg L, Ellrott K, Yuan Y, et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet. 2013; 45: 1121-1126.
18. Ihaka R, Robert GR. A language for data analysis and graphics. J Comput Graph Stat. 1996; 5: 299-314.
19. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and computational biology. Methods Enzymol. 2006; 411: 119-134
20. Chang C, Lin C. LIBSVM: a library for support vector machines. Acm Trans Intell Syst Technol. 2011; 2: 21-27.
21. Guyon I, Weston J, Barnhill S, et al. Gene selection for cancer classification using support vector machines. Mach Learn. 2002; 46: 389-422.
22. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003; 56: 1129-1135.
23. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012; 40: W478-W483.
24. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1, 550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009; 27: 2503-2508.
25. Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012; 18: 3952-3960.
26. Weiss LM, Chu P, Schroeder BE, et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn. 2013; 15: 263-269.
27. Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med. 2007; 131: 1561-1567.
28. Mashkoor FC, Al-Asadi JN, Al-Naama LM. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013; 37: 613-618.
29. Kucera E, Kainz C, Tempfer C, et al. Prostate specific antigen (PSA) in breast and ovarian cancer. Anticancer Res. 1997; 17: 4735-4737.
30. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015; 16: e342-e351.
31. Furnari FB, Cloughesy TF, Cavenee WK, et al. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015; 15: 302-310.
32. Giampieri R, Aprile G, Del Prete M, et al. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients. Curr Drug Targets. 2014; 15: 1225-1230.
33. Teng HW, Wang HW, Chen WM, et al. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol. 2011; 103: 773-781.
34. Li Q, Tang Y, Cheng X, et al. EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol. 2014; 7: 733-741.
35. Li JC, Zhao YH, Wang XY, et al. Clinical significance of the expression of EGFR signaling pathway-related proteins in esophageal squamous cell carcinoma. Tumor Biol. 2014; 35: 651-657.
36. Li YX, Lu Y, Li CY, et al. Role of CDH1 promoter methylation in colorectal carcinogenesis: a metaanalysis. DNA Cell Biol. 2014; 33: 455-462.
37. Jing H, Dai F, Zhao C, et al. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer. Medicine (Baltimore) 2014; 93: e107.
38. Liu F, Li H, Chang H, et al. Identification of hepatocellular carcinoma-Associated hub genes and pathways by integrated microarray analysis. Tumori. 2015; 101: 206-214.
39. Angelescu C, Burada F, Ioana M, et al. VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers. Clin Transl Oncol. 2013; 15: 313-320.
40. Zhang H, Yang R. Resveratrol inhibits VEGF gene expression and proliferation of hepatocarcinoma cells. Hepatogastroenterology. 2014; 61: 410-412.
41. Kjaer-Frifeldt S, Fredslund R, Lindebjerg J, et al. Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. Pharmacogenomics. 2012; 13: 763-770.
42. Samartzis EP, Noske A, Dedes KJ, et al. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-Associated ovarian carcinomas. Int J Mol Sci. 2013; 14: 18824-18849.
43. Seidman JD, Zhao P, Yemelyanova A. 'Primary peritoneal' high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011; 120: 470-473.
44. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011; 42: 918-931.
45. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas. N Engl J Med. 2010; 363: 1532-1543.
46. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
47. Ojala KA, Kilpinen SK, Kallioniemi OP. Classification of unknown primary tumors with a data-driven method based on a large microarray reference database. Genome Med. 2011; 3: 63.
48. Monzon FA, Medeiros F, Lyons-Weiler M, et al. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol. 2010; 5: 3.
49. van Laar RK, Ma XJ, de Jong D, et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer. 2009; 125: 1390-1397.
50. Dumur CI, Lyons-Weiler M, Sciulli C, et al. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. J Mol Diagn. 2008; 10: 67-77.